IDEC vor Kursexplosion ??? - 500 Beiträge pro Seite

[781]

Heute werden nachbörslich super Zahlen erwartet, wird der
Kurs explodieren? Was meint ihr?

Gr. 781

[Lucky 1]

die haben gestern nachbörslich gemeldet.umsatz plus 44%
gruss

L1

[Lucky 1]

entschuldige,die zahlen kamen vor börseneröffnung.idec gut ,genentech nicht so berauschend.heute abend nachbörslich meldet immunex
gruss

L1

[781]

Das war nur ein Vorbericht.

[money_max]

Erstaunlich, das sich niemand für diesen Top-Wert interessiert!

PRUDENTIAL SECURITIES Comments for EBAY, IDPH, TER, OAKT and BEAS
By: PRUDENTIAL SECURITIES
9/21/00 7:04:19 AM


IDEC PHARMACEUTICALS (IDPH-$153 3/16-ACUM-TARGET $185)
* WE`VE RAISED OUR PRICE TARGET TO $185 (FROM $150), AND IMPLIES 20% UPSIDE FROM CURRENT LEVELS.
* WE ARE INCREASING OUR 2000-2003 RITUXAN ESTIMATES AS WE BELIEVE SALES GROWTH IS STRONGER THAN EXPECTED.
* OUR 3Q00 RITUXAN ESTIMATE INCREASES TO $109M FROM $102M AND IMPLIES 12% SEQUENTIAL GROWTH OVER 2Q, MAKING EPS $0.30 VS. OUR PRIOR $0.27.
* FY00 EPS FORECAST GOES TO $0.97 FROM $0.91, FY01 NOW $1.45 WAS $1.41.
* AN INVENTORY ANALYSIS SHOWED NO STOCKING ISSUES AND WE ANTICIPATE ANOTHER "CLEAN" RITUXAN QUARTER.




money_max

[187]

Hallo Leute !!!!
Ich finde es auch erstaunlich das sich hier niemand für idec interresiert.Ich bin in den Titel schon eine ganz weile und muß sagen das der Kursverlauf mindetens genau so gut ist wie bei Vertex,Millenium usw.(wenn nicht besser).
Jedenfalls wüde ich mich freuen wenn über IDEC nicht so taotal vernachlässicht wird.
Bitte um Meinungen

Gruß 187

[Ichweissauchnicht]

Hallo, IDEC-Fans
ich bin heute durch bigcharts.com auf IDEC aufmerksam geworden, die sind innerhalb von 5 Jahren um über
4000% gestiegen, muß wirklich ein toller Wert sein. Vielleicht sollte man einsteigen.....

[money_max]

@Ichweissauchnicht

Stimmt genau! Vor allem werden wir dank "Rituxan" wider mit Top-Quartalszahlen rechnen können.


The Wall Street Transcript Publishes Biotechnology Report In Banc Of America Securities Annual Investment Conference Issue
Friday September 22, 7:00 am Eastern Time

In an in-depth (4,700 words) Analyst Interview, Dr. Eric Ende, Senior Research Analyst at Banc of America Securities, examines the outlook for the sector, including human genome project, genomic-based therapies, and shares specific stock recommendations.

Ende explains, "I focus on companies that have products that have pretty good Phase II data. The probability of a drug in Phase I development ever making it to market is only, on average, about 20%. The likelihood of a drug in Phase II getting to market is about 30%-33%. However, if a drug is in Phase III (and you can infer that you have Phase II data), the probability of that drug getting to market is closer to 65%. So you eliminate a lot of the risk by focusing on the Phase III product companies."

Ende reports on IDEC Pharmaceuticals "If you think about why people should be buying biotech, it is really because they are high-growth stories. But that alone is not enough. I think you have to have a high-growth story that has sustainable growth prospects, that`s the important point, and IDEC has exactly that. They have Rituxan for non-Hodgkin`s lymphoma and the drug is selling extremely well. We saw it reaccelerate in the second quarter, and we`re expecting that reacceleration to continue. Sales in the third quarter look pretty strong as well. And that`s just one source from which we`ll be able to see a 40%-plus growth rate."


money_max

[money_max]

neues ATH

[money_max]

Wednesday September 27, 8:16 am Eastern Time

FDA Issues ``Completed Review`` Letter On Expanded Studies of Rituxan -- Rituximab --

SAN DIEGO--(BW HealthWire)--Sept. 27, 2000--IDEC Pharmaceuticals Corporation announced today that it had received a ``completed review`` letter from the U.S. Food and Drug Administration (FDA) indicating that it has completed review of a supplemental Biological License Application (sBLA) for Rituxan® (Rituximab).

IDEC submitted the sBLA in late 1999 based on studies in non-Hodgkin`s lymphoma (NHL) of Rituxan: 1) treatment of patients with bulky disease, 2) provide for dosing of up to eight weekly doses per treatment, and 3) multiple courses of treatment.

During the review process, IDEC provided the FDA with proposed revisions and additions to the Rituxan Package Insert (PI). In its ``completed review`` letter, the FDA commented only on the details of the PI.

Based on the FDA`s comments, IDEC will begin discussions with the FDA with the objective of finalizing revisions to the Rituxan PI.

Originally approved by the FDA in November 1997, Rituxan is indicated for the treatment of patients with relapsed or refractory, low grade or follicular, CD20 positive, B-cell NHL. Rituxan was discovered by IDEC and is jointly developed by IDEC, Genentech Inc., F. Hoffmann-La Roche Ltd. of Switzerland and Zenyaku Kogyo Co. Ltd. of Japan. Roche has marketing rights to Rituximab outside of the United States and Japan. Worldwide, Rituxan is approved for use in 55 countries.

[Carramba]

jetzt bei 200 € noch einsteigen ?
bio`s sind ja schon gut gelaufen.
IDEC kämft wohl gerade mit der überwindung des alten ATH, ist der ausbruch schon "signifikant" ? so viele fragen ,keine antworten -könnt ihr mir helfen habt ihr irgendwelche news ?

dausent dank Carramba

[money_max]

@Carramba

Kurzfristig würde ich trotz des neuen ATH vom Einstieg abraten.
Falls du langfristig orientiert bist, lohnt sich ein Einstieg aber immer. Ansonsten könntest du auch kurzfristig auf gute Quartalszahlen spekulieren.
Alle neueren News findest in diesem Thread.

money_max

[money_max]

@Carramba
Das sagen die "Profis" dazu:

26.09.00
IDEC Pharma hoch bewertet
Report21

Die Analysten vom Börsenbrief Report21 raten Interessierten, die Aktie der IDEC Pharmaceuticals Corporation (WKN 883218) erst bei Kursen unter 100 US-Dollar zu kaufen.

Das Biotech-Unternehmen habe sich auf die Erforschung, Entwicklung und Kommerzialisierung von neuen Therapien zur Bekämpfung von Krebs, Autoimmunerkrankungen und Entzündungen spezialisiert.

Das erste kommerzielle Produkt des Unternehmens, Rituxan, und das am weitesten fortgeschrittene Folgeprodukt „Zevalin“ würden zur Behandlung der Krebsart Non-Hodgkin´s Disease eingesetzt.

Zevalin stelle ein Ergänzungsprodukt zu Rituxan dar und verbinde die zielgenaue Erkennung von Antigenen durch Antikörper mit der krebstötenden Wirkung von Strahlung. Damit stelle IDEC eine sichere, effektivere Strahlentherapie als die konventionelle Chemotherapie zur Verfügung.

In den ersten sechs Monaten des laufenden Geschäftsjahres habe das Unternehmen den Umsatz gegenüber dem Vorjahreszeitraum um 13% auf 55,8 Millionen USD gesteigert, aber beim Nettogewinn einen Rückgang um 32% auf 16,9 Millionen USD hinnehmen müssen.

Fundamental sei das Papier sehr hoch bewertet. Neuinvestitionen sollten erst bei Kursen unter 100 USD getätigt werden, so das Researchteam.



MFG
money_max

[Carramba]

danke für die infos werde versuchen mit der hälfte des einsatzes bei 170-180 € reinzukommen.
euch allen noch viel erfolg mfg Carramba

[money_max]

Wednesday November 1, 5:00 pm Eastern Time
IDEC Pharmaceuticals Submits Biologics License Application for ZEVALIN Radioimmunotherapy to the U.S. Food and Drug Administration

IDEC Pharmaceuticals Corporation today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval of ZEVALIN(TM) (Ibritumomab Tiuxetan). This radioimmunotherapy is proposed for the treatment of low grade or follicular, relapsed or refractory, CD20-positive, B-cell non-Hodgkin`s lymphoma (NHL) and Rituximab-refractory follicular NHL, which is cancer of the lymphatic system.

IDEC also noted the FDA had designated ZEVALIN a Fast Track Product for the treatment of relapsed or refractory, low grade or follicular NHL. Under the FDA Modernization Act of 1997, designation as a Fast Track Product means that the FDA will facilitate the development and expedite the review of a drug if it is intended for the treatment of a serious or life-threatening condition, and it demonstrates the potential to address unmet medical needs for such a condition.

Acceptance for review of the license application by the FDA will be determined within 60 days of submission.

``This submission is a tremendous achievement for IDEC and highlights our commitment to developing innovative and complementary therapies for the treatment of non-Hodgkin`s lymphoma,`` said William H. Rastetter, IDEC`s chairman, chief executive officer and president. ``This application is the result of the collective effort of hundreds of IDEC employees. Some have worked years to bring ZEVALIN to this stage, with the hope that ZEVALIN might benefit NHL patients.``

IDEC`s partner Schering A.G., which has worldwide marketing rights to ZEVALIN, except in the United States, also plans to submit a Marketing Authorization Application (MAA) for ZEVALIN to the European Medicines Evaluation Agency (EMEA).

Electronic Filing

IDEC`s ZEVALIN filing consists of seven compact disks (CDs) and approximately 30 more CDs of digitized computer tomography (CT) scans and nuclear medicine images. This is one of the first BLAs submitted to the FDA in a completely electronic format; no paper version is required to accompany the CDs.

The BLA submission is based on clinical data from two Phase III trials conducted by IDEC at approximately 30 medical sites in the United States. One pivotal trial was a randomized-controlled study of ZEVALIN versus a standard course of Rituxan® (Rituximab). The second trial studied ZEVALIN in Rituxan-refractory patients with follicular NHL. Data from both studies will be presented at the American Society of Hematology (ASH) in early December 2000.

IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for the treatment of cancer and autoimmune diseases. IDEC`s antibody products act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient`s blood or lymphatic systems. For a menu of IDEC`s current news releases and quarterly reports or to retrieve a specific release, call [phone]. On the Internet check the News Center at IDEC`s website: http://www.idecpharm.com.

The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from IDEC`s expectations. For example, the timing, success and cost of preclinical research and clinical studies, the timing, acceptability and review periods for regulatory filings, the timing of and ability to obtain regulatory approval of products, such as ZEVALIN, the achievement of future product sales, the level of manufacturing performance and the risk factors listed from time to time in IDEC`s SEC filings including but not limited to its Annual Report on Form 10-K for the year ended December 31, 1999 and Form 10-Q for the quarter ended June 30, 2000, may affect the actual results achieved by IDEC. These forward-looking statements represent the company`s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.


Die Party kann weitergehen!

money_max

[money_max]

WEDNESDAY, NOVEMBER 01, 2000 4:40 PM
IDEC Pharmaceuticals Selected Today to Receive Peter McCuen Cancer Research Award

Informed Investors, Inc., announced at a press conference today that IDEC Pharmaceuticals Corp. (Nasdaq: IDPH) has been selected to receive the Peter McCuen Cancer Research Award this Saturday at the UC Davis Cancer Center benefit dinner.

McCuen, a prominent Sacramento developer and chairman of the UC Davis Cancer Center board, died of prostate cancer in 1999 at the age of 64. McCuen is credited with helping to change the economic landscape of Sacramento.

"Peter saw great opportunity in this region for the research program of the UC Davis Cancer Center," said Thomas Hobday, assistant dean of Health Sciences Advancement and Public Affairs at the UC Davis Medical Center. "He helped develop the vision for the cancer center of becoming a premier cancer research program. This award reflects the cancer center`s progress."

The award recognizes outstanding corporate achievement in the battle against cancer. San Diego based IDEC Pharmaceuticals was chosen for developing Rituxan, a groundbreaking new treatment for B-cell non-Hodgkin`s lymphoma, a disease that afflicts some 275,000 Americans.

The McCuen Award will be officially conveyed at the UC Davis Cancer Center annual benefit dinner Saturday evening, November 4th, at the Sacramento Hilton. Accepting the award on behalf of IDEC Pharmaceuticals will be Antonio Grillo-Lopez, M.D., Chief Medical Officer for IDEC, and the driving force behind the discovery and development of Rituxan.

[money_max]

THURSDAY, JANUARY 11, 2001 7:58 AM
IDEC Pharmaceuticals Begins Phase II Study in Psoriasis With Its Primatized Antibody, IDEC-114


IDEC Pharmaceuticals today announced that it has initiated a randomized Phase II clinical trial with its investigational agent, IDEC-114, a PRIMATIZED(R) anti-CD80 (anti-B7-1) monoclonal antibody. The blinded, placebo-controlled, multiple-dose study will evaluate the potential clinical activity and safety of this investigational agent in patients with moderate to severe psoriasis.

"We are very pleased with the results of our recently completed Phase I/II trial with IDEC-114 in psoriasis," said Richard G. Lizambri, M.D., director, Autoimmmune and Inflammatory Diseases. "This multiple-dose trial has confirmed and extended the favorable safety profile and preliminary evidence of clinical activity seen in our earlier Phase I trial." Detailed results from this study will be presented at a major scientific conference this year.

IDEC-114 has the potential to selectively regulate the immune response by binding to CD80, a key co-stimulatory molecule on antigen-presenting cells. Because IDEC-114 is highly targeted to cells that are directly related to the pathogenesis of psoriasis, it has the potential to achieve clinical activity while maintaining a very favorable safety profile.

Mitsubishi-Tokyo Pharmaceuticals, Inc. has licensed the commercial rights of IDEC-114 in Asia. IDEC retains exclusive rights outside of Asia.

[money_max]

Thursday, January 18, 2001

IDEC Pharmaceutical positive

IDEC Pharmaceuticals shares could get a lift in trading due to the company’s announcement fourth-quarter earnings will be higher than expected as a result of sales of Rituxan. The company said earnings would be about 37 cents a share, while analysts had been expecting a profit of 11 cents a share . The company said its collaboration with Genetech to sale Rituxan resulted in $134 million in sales for the quarter.

By Barbara C. Costanza
CBS MarketWatch.com
-----------------------------------------------------------------------------------------------------------

IDEC Pharmaceuticals Announces Net U.S. Rituxan Sales of $134.0 Million in Fourth Quarter, 2000, and $424.3 Million for the Year 2000
THURSDAY, JANUARY 18, 2001 4:54 PM


Following Genentech`s fourth quarter earnings release, IDEC Pharmaceuticals Corporation today announced that the collaboration between IDEC and Genentech, Inc. achieved U.S. net sales of Rituxan(R) (Rituximab) totaling $134.0 million for the three months ending December 31, 2000. U.S. net sales of Rituxan for the full year 2000 were $424.3 million, compared to $262.7 million for 1999. This level of sales results in a preliminary net income estimate for IDEC of approximately $0.37 per share on a diluted basis for the fourth quarter of 2000 and $0.91 per share on a diluted basis for the full year 2000.

IDEC`s fourth quarter and full year results have been adjusted to reflect implementation of the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 101.

IDEC`s full financial results for the fourth quarter are expected to be released on January 29, 2001, after the close of market. Following the release, IDEC will conduct a live webcast of a discussion by IDEC management of the financial results between 1:30-2:30 p.m. PST. The webcast will be accessible through a link at IDEC`s website at www.idecpharm.com and will remain available for 48 hours.

"Sales performance for Rituxan in the fourth quarter and the entire year shows the importance Rituxan has attained after three years of commercialization in the management of certain B cell non-Hodgkin`s lymphomas," said William R. Rohn, IDEC`s chief operating officer. "Net sales for the past year are up 62 percent compared to 1999, and fourth quarter sales this year are up 86 percent, compared to the fourth quarter last year."

SAB No. 101 provides that nonrefundable up-front fees received under collaborative agreements be recognized over future periods rather than upon payment. The cumulative effect of changing the accounting policy for the company`s recognition of up-front nonrefundable fees received under collaborative agreements will result in a non-cash charge to earnings of $9.3 million net of tax for the year ended December 31, 2000. Also resulting from the implementation of SAB No. 101, the company will recognize $1.6 million and $6.5 million in license fee revenue for the three months and year ended December 31, 2000, respectively. If IDEC had not been required to implement SAB No. 101, the reported earnings per share estimate on a diluted basis would have been $0.35 and $0.98 per share for the three months and year ended December 31, 2000, respectively.

The net sales of Rituxan reported by Genentech in the fourth quarter included $4.3 million of ex-US sales to its partner F. Hoffmann-La Roche Ltd. IDEC`s royalty revenue on sales of Rituximab outside the U.S. is based on Roche`s end-user sales and is booked with a one-quarter lag. IDEC will recognize, during the fourth quarter of 2000, $2.3 million in royalties from Roche`s end-user sales during the third quarter.

PRNewswire
----------------------------------------------------------------------------------------------------------

IDEC Pharmaceuticals and Genentech to Support American Cancer Society Fellowship Program
THURSDAY, JANUARY 18, 2001 5:26 PM

ATLANTA, Jan 18, 2001 /PRNewswire via COMTEX/ -- The American Cancer Society, the nation`s leading voluntary health agency, announced today that IDEC Pharmaceuticals Corp. and Genentech, Inc. will sponsor a scientific research fellowship program, in honor of Ronald Levy, MD.

Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine, chief, division of oncology, Stanford University School of Medicine, and an American Cancer Society Clinical Research Professor.

The program, underwritten by both IDEC and Genentech will be funded through a gift given to the American Cancer Society Foundation. It will be managed by the Society, and will award research fellowships in the amount of $50,000 to two post-doctoral students each year for the next five years. "We applaud IDEC and Genentech for their commitment to funding the work of young cancer researchers," said Harmon J. Eyre, MD, the Society`s executive vice president for medical affairs and research. " The dedication of the fellowship to Dr. Levy and his accomplishments is further recognition of the enormous contributions he has made throughout his career to eliminating cancer as a major health problem."

In November, Dr. Levy received the American Cancer Society`s Medal of Honor, its most prestigious award, for "his conviction that the body`s natural defenses can be used to fight the diseases that attack it; for his search for novel approaches and new technologies to overcome cancer, especially immunologic treatments for lymphoma; for his research to create vaccines against cancer; and for his commitment to mentoring young investigators."

"By naming this research fellowship program in honor of Dr. Levy, we recognize his groundbreaking contribution in monoclonal antibody research for the treatment of non-Hodgkin`s lymphoma," said Antonio J. Grillo-Lopez, MD, IDEC`s chief medical officer, emeritus.

"Dr Levy is a true pioneer of innovative approaches to the treatment of cancer, especially lymphoma," said Gwen Fyfe, M.D., Genentech`s senior director of oncology. "His research has led directly to new therapies that have made a significant impact on the lives of many people with cancer. We are honored to sponsor this research fellowship in Dr. Levy`s name and look forward to his continued contributions, and the research of the fellowship recipients, in helping to eradicate cancer."

PRNewswire